 |
Previous Article | Next Article 
The Journal of Neuroscience, November 15, 2000, 20(22):8443-8451
Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both
Striatal Long-Term Depression and Long-Term Potentiation, Opposing
Forms of Synaptic Plasticity
Paolo
Calabresi1, 2,
Paolo
Gubellini1,
Diego
Centonze1, 2,
Barbara
Picconi1,
Giorgio
Bernardi1, 2,
Karima
Chergui3,
Per
Svenningsson3,
Allen A.
Fienberg3, and
Paul
Greengard3
1 Clinica Neurologica, Dipartimento di Neuroscienze,
Università di Tor Vergata, Rome, Italy, 2 Istituto di
Ricovero e Cura a Carattere Scientifico Ospedale Santa Lucia,
Rome, Italy, and 3 Laboratory of Molecular and Cellular
Neuroscience, The Rockefeller University, New York, New York 10021
 |
ABSTRACT |
A complex chain of intracellular signaling events, critically
important in motor control, is activated by the stimulation of D1-like
dopamine (DA) receptors in striatal neurons. At corticostriatal synapses on medium spiny neurons, we provide evidence that the D1-like
receptor-dependent activation of DA and cyclic adenosine 3',5'
monophosphate-regulated phosphoprotein 32 kDa is a crucial step for the
induction of both long-term depression (LTD) and long-term potentiation
(LTP), two opposing forms of synaptic plasticity. In addition,
formation of LTD and LTP requires the activation of protein kinase G
and protein kinase A, respectively, in striatal projection neurons.
These kinases appear to be stimulated by the activation of D1-like
receptors in distinct neuronal populations.
Key words:
basal ganglia; brain slices; dopamine; intracellular
recordings; nitric oxide synthase-positive interneurons; phosphatases; protein kinase C; protein kinase G
 |
INTRODUCTION |
Dopamine (DA)-containing fibers
arising from midbrain neurons and glutamatergic inputs originating from
the cortex extensively interact in the neostriatum to ensure correct
information processing through the basal ganglia. Degeneration of
DAergic terminals causes both an altered striatal glutamatergic
neurotransmission and the motor and cognitive deficits observed in
Parkinson's disease (Calabresi et al., 1997a ). At the cellular level,
both nigral DAergic inputs and cortical glutamatergic terminals
converge on the same striatal neuronal subtype, the spiny projection
neuron, which represents >90% of the striatal cell population and is
the only cell type projecting out of the striatum. Medium spiny neurons
contain both D1-like (D1, D5) and D2-like (D2, D3, D4) DA receptors
(Gerfen, 1992 ; Sibley and Monsma, 1992 ; Surmeier et al., 1996 ) and also express both NMDA and non-NMDA classes of ionotropic glutamate receptors (Calabresi et al., 1996 ; Gotz et al., 1997 ). In addition, DA
receptors are located in other critical sites in the striatum, such as
interneurons, which also express glutamate receptors (Le Moine et al.,
1991 ; Kawaguchi et al., 1995 ). This evidence suggests a complex action
of DA on striatal physiological activity.
DA receptor activation has been found to represent a critical factor in
the formation of two alternative forms of neuroplasticity at
corticostriatal synapses, long-term depression (LTD) (Calabresi et al.,
1992a ; Choi and Lovinger, 1997 ) and long-term potentiation (LTP)
(Centonze et al., 1999 ). Corticostriatal LTD, in fact, is prevented by
unilateral nigral lesions, by D1- or D2-like DA receptor antagonists
(Calabresi et al., 1992a ), and by genetic disruption of D2 receptors
(Calabresi et al., 1997b ). Similarly, DAergic denervation of the
striatum blocks LTP (Centonze et al., 1999 ). Striatal LTD and LTP are
elicited in vitro by repetitive activation of
corticostriatal glutamatergic terminals, in the presence and absence,
respectively, of external magnesium in the bathing solution. Nevertheless, it should be noted that some authors have observed striatal LTP even in physiological concentrations of magnesium, when
the experimental condition allows a certain activation of NMDA
glutamate receptors (Wickens et al., 1996 ; Charpier and Deniau, 1997 ;
Charpier et al., 1999 ; Dos Santos Villar and Walsh, 1999 ). Accordingly,
whereas LTD is expressed in the presence of NMDA receptor antagonists,
LTP is fully prevented by these pharmacological agents, indicating that
corticostriatal LTP, but not LTD, is dependent on NMDA glutamate
receptor activation (Calabresi et al., 1992b ). These enduring changes
in the efficacy of corticostriatal transmission may profoundly affect
the pattern of firing of striatal spiny neurons, because, in the intact
brain, the activity of striatal neurons mainly depends on the
release of glutamate from cortical terminals (Stern et al., 1998 ).
In the striatum, D1- and D2-like receptors trigger opposite effects on
intracellular levels of cAMP, stimulating and inhibiting adenylyl
cyclase activity, respectively. These effects modulate cAMP-dependent
protein kinase A (PKA) activity. A major substrate for PKA in spiny
neurons is the DA and cyclic adenosine 3',5' monophosphate-regulated
phosphoprotein 32 kDa (DARPP-32). This small protein is expressed in
very high concentrations in virtually all spiny neurons and acts, in
its phosphorylated but not dephosphorylated form, as a potent inhibitor
of protein phophatase-1 (PP-1). PP-1, in turn, regulates the
phosphorylation state and activity of many physiological effectors,
including NMDA and AMPA glutamate receptors (Greengard et al., 1999 ),
that are involved, respectively, in corticostriatal LTP and LTD
(Calabresi et al., 1992a ,b , 1996 ). The functional activity of these
receptors is also modulated by the direct action of PKA (Roche et al.,
1996 ; Tingley et al., 1997 ), as well as that of other kinases, such as
protein kinase C (PKC) (Roche et al., 1996 ; Tingley et al., 1997 ;
Carvalho et al., 1999 ). In addition, DARPP-32 also represents an
excellent substrate for protein kinase G (PKG) (Hemmings et al.,
1984a ,b ; Tsou et al., 1993 ), the activity of which is stimulated by
cytosolic cGMP.
The aim of the present study was to address how the concomitant
activation of ionotropic glutamate receptors and D1-like DA receptors
initiates a cascade of biochemical events leading to the formation of
opposing forms of corticostriatal plasticity, LTD and LTP.
 |
MATERIALS AND METHODS |
Electrophysiological experiments. Male wild-type (WT)
and DARPP-32 knock-out (KO) (Fienberg et al., 1998 ) mice (2-3
months) were used for the electrophysiological experiments. The
preparation and maintenance of coronal corticostriatal slices have been
described previously (Calabresi et al., 1990 , 1997b ). Briefly, coronal
slices (200-300 µm) were prepared from tissue blocks using a
vibratome. The slices included the neostriatum and the neocortex. A
single slice was transferred to a recording chamber (0.5 ml) and
submerged in a continuously flowing Krebs' solution (32-33°C, 2-3
ml/min) gassed with a 95% O2 and 5%
CO2 mixture and containing 10 µM bicuculline to avoid contamination of the
corticostriatal EPSPs with depolarizing GABAA-mediated potentials. The composition of the
solution was (in mM): 126 NaCl, 2.5 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 11 glucose, and 25 NaHCO3. For intracellular
recordings, sharp electrodes were used; they were filled with 2 M KCl (30-60 M ). An Axoclamp 2A amplifier
(Axon Instruments, Foster City, CA) was used for recordings either in
current-clamp or in voltage-clamp mode. In single-electrode
voltage-clamp mode, the switching frequency was 3 kHz. The headstage
signal was continuously monitored on a separate oscilloscope. Traces
were displayed on an oscilloscope and stored on a digital system. For
synaptic stimulation, bipolar electrodes were used. The stimulating
electrode was located either in the cortical areas close to the
recording electrode or in the white matter between the cortex and the
striatum. As the conditioning tetanus, we used three trains (3 sec
duration, 100 Hz frequency, at 20 sec intervals). The duration of each
individual pulse was 0.01-0.03 msec. During tetanic stimulation, the
intensity was increased to levels producing an action potential on the
EPSP (approximately twice the test intensity). Quantitative data on post-tetanic modifications are expressed as percentage of the controls,
the latter representing the mean of responses recorded during a stable
period (15-30 min) before tetanic stimulation or drug application.
Each data point in the graphs in figures was obtained from at least
five single neurons. Student's t test and
2 analysis (for paired and unpaired
observations) were used to compare the means, and ANOVA was used when
multiple comparisons were made against a single control group. Drugs
were applied by dissolving them to the desired final concentration in
saline and by switching the perfusion from control saline to
drug-containing saline. The following drugs were used:
D(-)-2-amino-5-phosphonopentanoic acid (APV),
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), SCH 23390, S-nitroso-N-acetylpenicillamine (SNAP),
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 7-nitroindazole
monosodium salt (7-NINA) (from Tocris Cookson, Bristol, UK),
calphostin C, nifedipine, phorbol 12,13-diacetate (PDAc) (Sigma-RBI,
St. Louis, Mo), bicuculline (Sigma), H89 (Calbiochem, La Jolla, CA),
zaprinast (Rhône-Poulenc Rorer, Dagenham, UK), okadaic acid, and
calyculin A (from Alexis, Läufelfingen, Switzerland).
Biochemical experiments. Male C57BL/6 mice (5-6
weeks old) were decapitated. Their brains were removed rapidly and
placed in ice-cold, oxygenated Krebs' solution. Coronal slices (300 µM) were prepared using a vibratome. For
high-frequency stimulation (HFS) experiments, each slice was placed in
the recording chamber and perfused with Krebs' solution containing
bicuculline (10 µM). The HFS of the
corticostriatal pathway was delivered as indicated above. For
experiments using SNAP and zaprinast, striata were dissected from the
slices in ice-cold Krebs' solution. Each slice was placed in a
polypropylene incubation tube with 2 ml of fresh Krebs' solution and
incubated at 30°C under constant oxygenation with 95%
O2 and 5% CO2. After a 30 min incubation, the buffer was replaced with fresh Krebs' solution
containing bicuculline (10 µM). After another
30 min, the slices were treated with SNAP (100 µM) or zaprinast (15 µM), plus bicuculline or with bicuculline only,
for 5, 10, or 20 min. After the drug or control treatment, the slices
were frozen rapidly on dry ice and stored at 80°C until assayed.
Frozen tissue samples were sonicated in 1% SDS and boiled for 10 min.
Aliquots (5 µl) of the homogenate were used for protein determination
according to the bicinchoninic acid protein assay method (Pierce,
Rockford, IL). Equal amounts of protein (25 µg; containing equal
amounts of DARPP-32) from each sample were loaded onto 10%
polyacrylamide gels. The proteins were separated by SDS-PAGE and
transferred to nitrocellulose membranes (0.2 µm) (Schleicher & Schuell, Keene, NH) by the method of Towbin et al. (1979) .
Phospho[Thr34]-DARPP-32 was
detected using a monoclonal antibody (mAb-23; 1:750 dilution) (Snyder
et al., 1992 ). Phospho[Thr75]-DARPP-32
was detected using purified rabbit antiserum (1:10,000 dilution) (Bibb
et al., 1999 ), and total DARPP-32 was detected using a mAb (1:10,000
dilution) (Hemmings et al., 1984a ). Antibody binding was revealed using
goat anti-mouse horseradish peroxidase-linked IgG (diluted 1:7500) for
phospho[Thr34]-DARPP-32 and
nonphosphorylated DARPP-32, a goat anti-rabbit horseradish
peroxidase-linked IgG (diluted 1:6000) for
phospho[Thr75]-DARPP-32, and the
enhanced chemiluminescence immunoblotting detection system (Amersham
Pharmacia Biotech, Arlington Heights, IL). Chemiluminescence was
detected by autoradiography. Quantification of the phospho-DARPP-32
bands was done by densitometry, using NIH Image (version 1.52)
software. Data were analyzed by one-way ANOVA followed by Dunnett's
test for paired comparisons. A statistical difference was defined as
p < 0.05.
 |
RESULTS |
Intrinsic and synaptic properties of striatal neurons in WT and
DARPP-32 KO mice
Conventional intracellular sharp microelectrode recordings were
performed in corticostriatal slices obtained from WT and DARPP-32 KO
mice. The intrinsic membrane properties of striatal neurons, such as
the resting membrane potential (RMP), input resistance, and
current-voltage relationship, did not significantly differ in neurons
recorded from the two groups of animals (WT: RMP = 85 ± 5 mV, input resistance = 42 ± 10 M , n = 50;
DARPP-32 KO: RMP = 84 ± 4, input resistance = 40 ± 13, n = 21; p > 0.05) and closely
resembled the electrical activity described previously for rat and
mouse spiny neurons (Fig.
1A,B) (Calabresi et
al., 1990 , 1997b ; Jiang and North, 1991 ). Also the pharmacology of cortically evoked EPSPs was similar in WT mice (n = 5)
and DARPP-32 KO mice (n = 5). In the presence of a
physiological concentration of external magnesium (1.2 mM), the AMPA glutamate receptor antagonist CNQX
(10 µM) fully suppressed the EPSPs in both
groups of animals. In contrast, in both groups, removal of external
magnesium, a procedure that removes the voltage-dependent block of NMDA
receptors, was necessary to uncover an NMDA component of the EPSP that
could be blocked by APV (50 µM) (Fig.
1C).

View larger version (23K):
[in this window]
[in a new window]
|
Figure 1.
Intrinsic and synaptic properties of striatal
spiny neurons recorded from WT and DARPP-32 KO mice. A,
Action potential discharge was induced by depolarizing current steps
(+0.9 nA) both in WT (a, RMP = 86 mV) and in
DARPP-32 KO (b, RMP = 85 mV) neurons.
B, Current-voltage plots obtained during
single-microelectrode voltage-clamp experiments from WT
(left) and DARPP-32 KO (right) neurons.
The membrane potential of both neurons was held at 85 mV.
C, In 1.2 mM magnesium, the blockade of
glutamate NMDA receptors by 30 µM APV did not affect the
EPSP recorded from striatal neurons from either WT
(a) or DARPP-32 KO (b)
mice. By contrast, in both experimental groups, the EPSP was fully
suppressed by coadministration of 30 µM APV plus 10 µM CNQX. The RMP of both neurons was 86 mV. In
magnesium-free medium, an APV-sensitive component was present in
striatal neurons in slices from both WT (c) and
DARPP-32 KO (d) mice. The RMP of both neurons was
86 mV.
|
|
Effects of high-frequency stimulation in WT and DARPP-32
KO mice
As previously described in rats (Calabresi et al., 1992a ,b , 1996 )
and mice (Calabresi et al., 1997b ), HFS (three trains, 100 Hz
frequency, 3 sec duration, 20 sec interval) of corticostriatal fibers
was able to produce long-term changes in the amplitude of EPSPs in WT
mice. In particular, a stable LTD was recorded in 1.2 mM
external magnesium (n = 12; Fig.
2A), whereas LTP was revealed after the removal of this ion from the bathing solution (n = 11; Fig. 2B). In contrast, both
forms of synaptic plasticity were absent in DARPP-32 KO mice
(n = 9 in 1.2 mM magnesium;
n = 10 in magnesium-free medium; p < 0.01 for both experimental conditions), indicating that changes
triggered by the stimulation of the DARPP-32/PP-1 signaling cascade are
critically involved in the formation of corticostriatal synaptic
plasticity (Fig. 2A,B). To test directly whether the
absence of both LTD and LTP in DARPP-32 KO mice was because of an
inability to inhibit PP-1 activity, we examined the effect of PP-1
inhibitors in DARPP-32 KO mice using the same experimental paradigm. In
DARPP-32 KO mice, bath application of okadaic acid (100 nM), an inhibitor of PP-1, restored both forms of
synaptic plasticity (n = 4 for each experimental condition, Fig. 2A,B). Similarly, another rather
selective inhibitor of this enzyme, calyculin A (100 nM), restored a normal LTP (n = 4; p > 0.05) and LTD (n = 4;
p > 0.05) These two inhibitors of PP-1 by themselves
had no effect on EPSP amplitude (p > 0.05).

View larger version (41K):
[in this window]
[in a new window]
|
Figure 2.
Role of DARPP-32 and PP-1 in the expression of
HFS-induced corticostriatal LTD and LTP. The graphs summarize the
results from intracellular experiments performed in the presence of
physiological concentrations of magnesium (A) and
in the absence of magnesium (B) from WT slices
(filled circles and squares),
DARPP-32 KO slices in control medium (open circles and
squares), and DARPP-32 KO slices bathed in medium
containing okadaic acid (OA) (open
triangles and diamonds). Okadaic acid was
applied 10 min before HFS was delivered. The arrows
indicate when HFS was delivered. The bottom part of the figure shows
EPSPs recorded in six neurons from WT slices (a, b),
DARPP-32 KO slices perfused in control medium (c, d),
and DARPP-32 KO slices bathed in okadaic acid (e,
f) immediately before (a, c, e) and 20 min after (b, d, f) HFS. RMPs were (in mV): 86
(A, WT and KO; B, WT), 84
(B, KO), and 82 (A, B, KO plus okadaic
acid).
|
|
Role of D1-like DA receptors and PKA in corticostriatal LTD
and LTP
In accordance with the idea that D1-like DA receptor stimulation
is the main factor required for DARPP-32 activation, we tested whether
the pharmacological blockade of this class of DA receptors was equally
effective in blocking both forms of synaptic plasticity. Consistently,
the D1-like DA receptor antagonist SCH 23990 (10 µM)
prevented both LTD, as reported earlier in rats (Calabresi et al.,
1992 ) (n = 6, p > 0.05), and LTP
(n = 11, p > 0.05) (Fig. 3) in WT mice. Activation of the D1-like
receptor stimulates PKA, leading to the phosphorylation of DARPP-32.
Therefore, we tested the effect of the selective PKA inhibitor H89 on
LTD and LTP. Surprisingly, in WT mice the intracellular injection of
H89 (100 µM) fully blocked LTP
(n = 5; p > 0.05) but failed to
prevent HFS-induced LTD (n = 6; p < 0.01) (Fig. 4). In contrast, when H89 (10 µM, n = 4 for each experimental
condition) was added to the perfusing solution, both LTD and LTP were
prevented (Fig. 4; p > 0.05 for both conditions).
These findings confirm the requirement of the D1-like receptor/PKA
pathway for corticostriatal LTD and LTP induction. However, these data
suggest different cellular loci for the action of PKA in the
development of LTP and LTD. Thus, for LTP but not for LTD, this pathway
is activated postsynaptically on spiny neurons. For LTD, it might be
activated in striatal neuronal subpopulations other than the recorded
spiny neurons.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 3.
The D1 DA receptor antagonist SCH 23390 blocks
both corticostriatal LTD and LTP in WT mice. The graphs summarize the
results obtained from intracellular experiments performed in WT mice in
the presence of a physiological concentration of magnesium
(A) and in the absence of magnesium
(B) in control medium (filled
circles and squares) and in the presence of 10 µM SCH 23390 (applied 10 min before HFS was delivered,
open circles and squares). The
arrows indicate when HFS was delivered. The
bottom part of the figure shows EPSPs recorded in four
neurons in control condition (a, b) and in the presence
of 10 µM SCH 23390 (c, d), immediately
before (a, c) and 20 min after (b, d)
HFS. RMPs were (in mV): 82 (A, control), 85
(A, SCH 23390), 87 (B, control) and
84 (B, SCH 23390).
|
|

View larger version (40K):
[in this window]
[in a new window]
|
Figure 4.
Role of PKA in the expression of HFS-induced
corticostriatal LTP and LTD. The graphs summarize the results obtained
in WT mice from intracellular experiments performed in the presence of
physiological concentrations of magnesium (A) and
in the absence of magnesium (B) in control
condition (filled circles and
squares), after intracellular injection of 100 µM H89, a PKA inhibitor (open circles and
squares), and after bath application of 10 µM H89 (10 min before HFS was delivered, open
triangles and diamonds). The
arrows indicate when HFS was delivered. The
bottom part of the figure shows EPSPs recorded in six
neurons in control condition (a, b), after intracellular
injection of 100 µM H89 (c, d), and in the
presence of bath-applied H89 (10 µM) (e,
f) immediately before (a, c, e) and 20 min after (b, d, e) HFS. RMPs were (in mV): 83
(A, control, intracellular, and bath-applied H89), 84
(B, bath-applied H89), and 88 (B,
control and intracellular H89).
|
|
Role of nitric oxide/cGMP pathway in corticostriatal LTD recorded
from WT and DARPP-32 KO mice
The sustained activation of glutamate receptors occurring during
HFS of corticostriatal fibers triggers the massive release of
endogenous DA from nigrostriatal terminals and also stimulates other
intrastriatal neuronal subtypes, such as nitric oxide synthase (NOS)-positive and cholinergic striatal interneurons (Calabresi et al.,
1999a ,b ). Nitric oxide (NO) and acetylcholine are critical transmitters
involved in striatal synaptic plasticity, by promoting through a
feed-forward mechanism the stimulation of different signaling pathways
in spiny projection neurons. In particular, the stimulation of the
NO/cGMP/PKG pathway, and of postsynaptic muscarinic M1 receptors
leading to PKC activation, is required for LTD (Calabresi et al.,
1999a ) and LTP (Calabresi et al., 1999b ), respectively. It is possible,
therefore, that the absence of both striatal LTD and LTP in DARPP-32 KO
mice might depend not only on interference with the D1 DA
receptor-initiated intracellular signaling systems but also with these
additional signal transduction mechanisms. For instance, activation of
the NO/cGMP/PKG pathway should lead to increased phosphorylation of
DARPP-32 (Greengard et al., 1999 ), and so one could predict an effect
of the DARPP-32 KO on this pathway. Similarly, the absence of PP-1
inhibition in DARPP-32 KO mice, by causing an elevated phosphatase
activity, might counteract the action of PKC on NMDA receptors.
To address these issues, several types of experiments have been
performed. It has been reported that the intracellular blockade of PKG
fully prevents HFS-induced LTD, suggesting a key role for this kinase
in this phenomenon (Calabresi et al., 1999a ). Conversely, pharmacological stimulation of the NO/cGMP/PKG pathway is able to
induce corticostriatal LTD. To test whether stimulation of DARPP-32 was
required for the induction of this pharmacological LTD, we studied the
effect of both the NO donor SNAP (100 µM) and the
selective cGMP-phosphodiesterase inhibitor zaprinast (15 µM) in DARPP-32 KO mice. Incubation of the slices with
SNAP (WT, n = 5; DARPP-32 KO, n = 7) or
zaprinast (WT, n = 6; DARPP-32 KO, n = 7) induced corticostriatal LTD in WT animals (p < 0.01 for both experimental conditions) but not in DARPP-32 KO
animals (p > 0.05 for both conditions) (Fig.
5), suggesting that DARPP-32 represents a
critical effector in this pharmacological LTD as in HFS-induced LTD.
When applied intracellularly, zaprinast (100 µM) depressed EPSP amplitude in WT mice
(n = 5; p < 0.01) but not in DARPP-32
KO mice (n = 5; p > 0.05), further
suggesting a role for postsynaptic cGMP elevation in LTD. Furthermore,
as seen for HFS-induced LTD and LTP (Fig. 2), bath application of okadaic acid (100 nM, n = 4 and
p > 0.05 for each experimental condition) restored
zaprinast- and SNAP-induced LTD in DARPP-32 KO mice (Fig. 5).

View larger version (37K):
[in this window]
[in a new window]
|
Figure 5.
Stimulation of the NO/cGMP pathway induces AMPA
receptor-mediated corticostriatal LTD in WT but not in DARPP-32 KO
mice. A, In the presence of 1.2 mM magnesium
plus 30 µM APV, the cGMP phosphodiesterase inhibitor
zaprinast induced LTD of AMPA-mediated EPSPs in WT mice
(filled circles) but not in DARPP-32 KO mice
(open circles). In these mutant animals, the
pharmacological LTD was restored after the application (10 min before
zaprinast application) of the PP-1 inhibitor okadaic acid (100 nM, open triangles). The bottom
part of the figure shows EPSPs recorded in neurons from WT
(a, b) and DARPP-32 KO (c-f) mice
immediately before (a, c, e) and 20 min after (b,
d, f) the application of zaprinast. The RMP of neurons
was 86 mV. B, In the presence of 1.2 mM
magnesium plus 30 µM APV, the NO donor SNAP induced LTD
of AMPA-mediated EPSPs in WT (filled squares) but
not DARPP-32 KO (open squares) mice. In these mutant
animals the SNAP-induced LTD was restored after the bath application
(10 min before SNAP application) of 100 nM okadaic acid
(open diamonds). The bottom part of the
figure shows EPSPs recorded in neurons from WT (a, b)
and DARPP-32 KO (c-f) mice immediately before
(a, c, e) and 20 min after (b, d,
f) the application of SNAP). RMPs were (in mV): 85
(WT) and 84 (DARPP-32 KO).
|
|
High-frequency stimulation, SNAP, and zaprinast increase Thr34 and
Thr75 phosphorylation of striatal DARPP-32
The electrophysiological data presented above indicate that
both HFS of corticostriatal fibers and pharmacological stimulation of
the NO/cGMP pathway by SNAP or zaprinast induce striatal synaptic plasticity by stimulating DARPP-32 activity. To further address this
idea, we measured the effects of HFS, SNAP, and zaprinast on the
phosphorylation state of DARPP-32 at its Thr34 residue, a measure of
its ability to serve as an inhibitor of PP-1. In addition, because it
has been shown recently that DARPP-32 acts as an inhibitor of PKA when
phosphorylated at Thr75 (Bibb et al., 1999 ), we evaluated the ability
of HFS, SNAP, and zaprinast to modulate this additional phosphorylation
site. As shown in Figure 6, HFS of
corticostriatal fibers, 100 µM SNAP, and 15 µM zaprinast were each able to increase significantly
both Thr34 and Thr75 phosphorylation of DARPP-32 in corticostriatal
slices, further confirming that the different induction protocols used
to elicit striatal synaptic plasticity also modulate the physiological
activity of DARPP-32.

View larger version (36K):
[in this window]
[in a new window]
|
Figure 6.
Effect of HFS (A, D), SNAP
(B, E), and zaprinast (C, F) on
the level of phospho[Thr34]-DARPP-32
(A-C) and
phospho[Thr75]-DARPP-32
(D-F) in striatal slices. The amount of
phospho-DARPP-32 was normalized to the level of total DARPP-32 in each
sample and is expressed as a percentage of that measured in control
slices. Data represent means ± SEM for four experiments performed
in duplicate or triplicate (n = 9-12).
*p < 0.05 versus the control group; ANOVA was
followed by Dunnett's test. The top lanes above each
graph illustrate phospho-DARPP-32. The bottom lanes
illustrate the corresponding total DARPP-32.
|
|
Role of D1-like/PKA pathway in pharmacological LTD
To evaluate the possible involvement of the activation of
the D1-like DA receptor and of PKA in the formation of SNAP- and zaprinast-induced LTD, we examined the effect of the PKA inhibitor H89
and of the D1-like DA receptor antagonist SCH 23390 on pharmacological LTD in WT mice. In experiments using intracellular H89
(n = 6), the LTD induced by SNAP was not significantly
different from the control LTD ( 41% ± 3 at 30 min after
HFS, p > 0.05). Similar results were obtained with
SCH 23390 (n = 6, 40% ± 4 at 30 min after HFS,
p > 0.05). H89 and SCH 23390 also failed to
significantly affect zaprinast-induced corticostriatal LTD
(n = 6 for each condition, p > 0.05).
It has been demonstrated that D1-like receptors stimulate striatal
NOS-positive interneurons and increase cGMP level (Altar et al.,
1990 ; Morris et al., 1997 ). Those results, taken together with the
evidence that D1 receptor activation is required for HFS-induced LTD,
but not for pharmacological LTD, indicate that the D1 receptor lies
upstream of NO activation of guanylyl cyclase in HFS-induced LTD.
Absence of role of NO/cGMP pathway in corticostriatal LTP
We subsequently evaluated whether stimulation of the
NO/cGMP/PKG/DARPP-32 pathway was involved in corticostriatal LTP. In magnesium-free external solution plus 10 µM CNQX, a
purely NMDA-mediated EPSP was obtained after the stimulation of
corticostriatal terminals in both WT and DARPP-32 KO mice. In this
condition, application of zaprinast (15 µM) (WT,
n = 5; DARPP-32 KO, n = 7) or SNAP (100 µM) (WT, n = 5; DARPP-32 KO,
n = 5) to increase intracellular cGMP levels failed to
produce significant changes in the amplitude and duration of the EPSPs,
either in WT animals or in DARPP-32 KO mice (p > 0.05 in both groups of animals).
We also studied the effects on HFS-induced LTP of the NOS inhibitor
7-NINA and of ODQ, a potent and selective inhibitor of soluble
NO-sensitive guanylyl cyclase. In previous studies, both agents have
been found to be capable of fully blocking corticostriatal LTD in the
rat (Calabresi et al., 1999a ), and do so in WT mice as well (Fig.
7A). In contrast, incubation
of corticostriatal slices from WT mice with 7-NINA (n = 5) or ODQ (n = 5) failed to prevent HFS-induced LTP
(Fig. 7B), supporting the idea that the stimulation of the
NO/cGMP/PKG pathway is not involved in the cellular changes necessary
for the formation of this form of synaptic plasticity.

View larger version (36K):
[in this window]
[in a new window]
|
Figure 7.
Inhibition of the NO/cGMP pathway blocks
corticostriatal LTD but not LTP in WT mice. The graphs summarize the
results obtained in WT mice in 1.2 mM magnesium
(A) and in the absence of magnesium
(B) in control condition (filled
circles and squares), in the presence of the
neuronal NOS inhibitor 7-NINA (10 µM, open
circles and diamonds), and in the presence of
the soluble guanylyl cyclase inhibitor ODQ (10 µM,
open squares and triangles). 7-NINA and
ODQ were applied 10 min before HFS was delivered. The
arrows indicate when HFS was delivered. The
bottom part of the figure shows EPSPs recorded from six
neurons in control condition (a, b), in the presence of
10 µM 7-NINA (c, d) and in the presence of
10 µM ODQ (e, f) immediately before
(a, c, e) and 20 min after (b, d,
f) HFS of the corticostriatal pathway. RMPs were (in
mV): 86 (A, control), 85 (A, 7-NINA),
80 (A, ODQ; B, 7-NINA), 81 (B,
control), and 88 (B, ODQ).
|
|
Role of PKC in corticostriatal LTP
In rat corticostriatal slices, PDAc, an activator of PKC,
increases the membrane depolarization produced by exogenous NMDA application (Pisani et al., 1997 ). This PKC-dependent enhancement of
NMDA currents represents a possible mechanism underlying
corticostriatal LTP. Conversely, M1 muscarinic receptor antagonists
prevent LTP by blocking PKC stimulation (Calabresi et al., 1999b ,
2000 ). To further define the role of PKC in corticostriatal LTP and to
study the possible interaction with the D1/cAMP/PKA/DARPP-32 pathway, we first tested whether pharmacological inhibition of PKC activity by
calphostin C (0.3 µM) altered the expression of LTP in WT
mice. As shown in Figure
8A, this PKC inhibitor
fully prevented the expression of this form of synaptic plasticity
(n = 5; p > 0.05). One possible
explanation for the absence of LTP in DARPP-32 KO mice is that, in
these animals, the lack of this physiological inhibitor of PP-1
decreases the phosphorylation state at the PKC site of the NMDA
receptor. According to this hypothesis, phosphorylation by PKC and
inhibition of dephosphorylation by the D1/cAMP/PKA/DARPP-32/PP-1 pathway, both of which are important for LTP, might synergistically interact to increase the phosphorylation state of the NMDA receptor at
this PKC site. To test this possibility, we measured the effects produced by PDAc (0.1-10 µM) on NMDA-mediated
EPSPs recorded from WT and DARPP-32 KO mice. Stimulation of PKC
activity by PDAc produced a dose-dependent increase in the amplitude of
the NMDA-mediated corticostriatal EPSPs in both groups of mice (Fig.
8B) (WT, n = 15; DARPP-32 KO,
n = 15). In DARPP-32 KO mice, however, we observed a
shift to the right of the dose-response curve for PDAc, suggesting that the phosphorylation state of the NMDA receptor is critically dependent both on PKC-mediated phosphorylation and PP-1-mediated dephosphorylation. Stimulation of PKC activity did not result in
significant changes in AMPA-mediated synaptic potentials in either WT
(n = 5) or DARPP-32 KO (n = 5) mice
(Fig. 8C), suggesting that PKC-dependent enhancement of
glutamate ionotropic-mediated transmission in the striatum is specific
for NMDA receptors.

View larger version (22K):
[in this window]
[in a new window]
|
Figure 8.
PKC activity is required for striatal LTP.
A, Blockade of PKC function by the selective inhibitor
calphostin C (0.3 µM) prevented LTP in WT mice. The
arrow indicates when HFS was delivered.
B, In magnesium-free solution plus 10 µM
CNQX, the stimulation of PKC activity by PDAc (applied for 10 min)
produces a dose-dependent enhancement of the cortically evoked
NMDA-mediated EPSPs in both WT (filled circles)
and DARPP-32 KO (open circles) mice. Note that
disruption of the DARPP-32 gene significantly reduced the PDAc-induced
enhancement of NMDA-mediated EPSPs (*p < 0.05;
**p < 0.01). C, In both WT
(filled squares) and DARPP-32 KO (open
squares) mice, the AMPA component of corticostriatal EPSPs,
recorded in the presence of a physiological concentration of external
magnesium plus 30 µM APV, was not modified by PDAc.
|
|
Effects of nifedipine on corticostriatal LTP
An elevation of intracellular calcium is a critical event leading
to LTP (Schiller et al., 1998 ). This elevation may be caused simply by
the activation of NMDA receptors. However, because it has been shown
that activation of the D1/cAMP/PKA/DARPP-32/PP-1 pathway enhances
L-type calcium currents (Surmeier et al., 1995 ), it also seemed
possible that these channels might contribute to LTP induction.
Therefore, we tested the pharmacological effects of nifedipine, a
blocker of L-type calcium channels, on the expression of this form of
synaptic plasticity. Nifedipine (10 µM, 10 min, n = 5, p > 0.05) did not alter the
amplitude or duration of HFS-induced corticostriatal LTP (data not
shown), ruling out the possibility that the control of LTP by the
D1/cAMP/PKA/DARPP-32/PP-1 pathway is exerted through the modulation of
L-type calcium channels.
 |
DISCUSSION |
This study provides the first evidence that activation of
DARPP-32, and the resultant inhibition of PP-1 activity, is of critical importance for the expression of two opposing forms of brain synaptic plasticity, striatal LTD and LTP. Both forms of plasticity are also
critically linked to the activation of DA receptors, supporting the
idea that in the striatum, a close interplay among DA receptors, DARPP-32 activity, and glutamatergic transmission might underlie the
functional role of this structure in motor control and cognitive activities. Moreover, alterations of these transduction pathways might
play a role in pathophysiological conditions involving striatal DAergic
mechanisms, such as Parkinson's disease, Huntington's disease, and schizophrenia.
Stimulation of D1/PKA/DARPP-32/PP-1 pathway is required for the
induction of both striatal LTD and LTP
In agreement with a previous report (Fienberg et al., 1998 ),
knocking out the DARPP-32 gene does not result in gross changes in the measured intrinsic membrane properties of recorded striatal spiny neurons. Similarly, the physiological and pharmacological properties of the glutamatergic EPSP evoked by a single cortical stimulation were not altered in DARPP-32 KO mice. In contrast, both LTP
and LTD were normally expressed in WT mice but fully abolished in
mutants. These findings are particularly interesting because these
forms of plasticity involve different ionotropic glutamate receptors:
activation of NMDA glutamate receptors is required for the expression
of striatal LTP but not for LTD. In addition, DAergic denervation
(Calabresi et al., 1992a ; Centonze et al., 1999 ) or blockade of D1-like
DA receptors abolishes both forms of synaptic plasticity. Although D1
receptor activation and DARPP-32 phosphorylation are involved in both
forms of synaptic plasticity, our data also provide evidence that LTD
and LTP require activation of distinct intermediate signaling steps in
spiny neurons. The demonstration that HFS, SNAP, and zaprinast each
increases the phosphorylation state of DARPP-32 in corticostriatal
slices further indicates that under our experimental conditions, the various induction protocols of striatal synaptic plasticity require DARPP-32 activation to be effective.
In WT mice, inhibition of PKA by intracellular application of H89
prevents the induction of LTP but not of LTD. Conversely, LTD, but not
LTP, is blocked by inhibitors of the NO/cGMP cascade and is mimicked by
the pharmacological stimulation of this signaling pathway.
The lack of effect of postsynaptic application of the PKA inhibitor H89
on LTD induction is an unexpected finding. In fact, previously
described electrophysiological effects mediated by D1-like receptor
activation involved PKA stimulation (Surmeier et al., 1995 ). However,
it is important to note that in isolated striatal neurons, stimulation
of PKA activity via D1-like receptor activation causes potentiation of
AMPA currents rather than their inhibition (Yan et al., 1999 ).
Interestingly, we found that bath application of the PKA inhibitor H89
was able to block HFS-induced LTD. Thus, it can be postulated that D1
receptors required for LTD expression are not located on spiny neurons
but on other neuronal subtypes such as NOS-positive interneurons
(Kawaguchi et al., 1995 ). In accordance with this interpretation,
evidence has been presented that activation of D1 receptors augments
striatal NO production (Morris et al., 1997 ). Thus,
D1-mediated increased NO levels might result in the activation of the
cGMP/DARPP-32 cascade (Hemmings et al., 1984a ,b ; Tsou et al.,
1993 ).
Various kinases are involved in the expression of corticostriatal
synaptic plasticity
The evidence that inhibition of either PKA or PKC is able to
prevent HFS-induced LTP and LTD suggests that the simultaneous activation of these kinases is required to induce these forms of
synaptic plasticity. Moreover, both forms of synaptic plasticity may
require both an increase in kinase activity and a decrease in
phosphatase activity, resulting in a synergistic increase in the state
of phosphorylation of residues on key substrate proteins such as AMPA
and NMDA receptors. This concept would explain for example why in
DARPP-32 KO mice relative to WT mice there is a reduced response to
various agonists such as DA, cocaine (Fienberg et al., 1998 ), and
phorbol esters (Fig. 7) at low but not at high concentrations of these
agonists. Thus, at high concentrations of these agonists, the
stimulation of kinase activity might be so great that the simultaneous
inhibition of phosphatase activity provided by DARPP-32 phosphorylation
would be unnecessary. The ability of zaprinast and SNAP to induce
pharmacological LTD may result from a synergistic action of activated
PKG, in which both an increased PKG-mediated direct phosphorylation of
substrate protein residues as well as a PKG/DARPP-32-mediated
inhibition of dephosphorylation of these substrate proteins occur. It
is also possible that zaprinast and SNAP induce a sufficiently strong inhibition of PP-1 to make the stimulation of phosphorylation by PKA or
PKC activity unnecessary.
The observation that the L-type calcium channel blocker nifedipine does
not affect HFS-induced LTP indicates that these channels, although
modulated by the DA-initiated intracellular pathway (Surmeier et al.,
1995 ), are not involved in LTP expression. It would be interesting to
test the effect of blockers of calcium channels other than L-type on
synaptic plasticity. Unfortunately, most of these drugs affect synaptic
transmission, precluding the possibility of testing their effects on
striatal plasticity. However, PKA and PKC might, by phosphorylating the
NMDA-receptor complex at two distinct sites, synergistically augment
the intracellular calcium concentration required for LTP. It has been
shown, in fact, that the NR1 subunit of NMDA-type glutamate receptors
is phosphorylated at Ser897 by PKA and at Ser890 by PKC (Tingley et
al., 1997 ; Greengard et al., 1999 ). Alternatively, PKA might increase
the state of phosphorylation of the NMDA receptor at the PKC-dependent
site by phosphorylating DARPP-32, thereby inhibiting PP-1-mediated
dephosphorylation of NMDA receptors at this site. In support of this
possibility, the phosphorylation of the PKC site is attenuated in
neurons from DARPP-32 KO mice in response to DA (Snyder et al., 1998 ).
In good agreement with these experimental findings, we found that
PDAc-mediated enhancement of the NMDA component of corticostriatal
EPSPs is significantly attenuated in DARPP-32 KO mice. It is
conceivable, therefore, that the simultaneous phosphorylation of the
NMDA-receptor complex at Ser897 and Ser890 by PKA and PKC,
respectively, coupled to the inhibition of PP-1-mediated dephosphorylation, may synergistically interact to ensure LTP generation at corticostriatal synapses.
Concluding remarks
DARPP-32 KO mice show a reduced behavioral response to drugs of
abuse such as cocaine and D-amphetamine. Moreover,
neuroleptic-induced catalepsy is severely attenuated in these animals
(Fienberg et al., 1998 ). These findings indicate that DARPP-32 controls
some mechanisms underlying reward-motivated behavior and DA-related motor control. We suggest that the DARPP-32-mediated control of DA-related behavioral activities may require long-term changes of
corticostriatal excitatory synaptic transmission, such as LTD and LTP.
The lack of gross behavioral alterations found in DARPP-32 KO mice does
not exclude the possibility that more subtle but equally important
changes might occur in these mice even in the absence of a
pharmacological challenge; these alterations might reflect the absence
of corticostriatal synaptic plasticity in these mice.
 |
FOOTNOTES |
Received June 26, 2000; revised Sept. 1, 2000; accepted Sept. 7, 2000.
This work was supported by a Biomed grant (P.C.), by a Telethon grant
(P.C.), by Consiglio Nazionale delle Ricerche grants (P.C. and
G.B.), by National Institutes of Health Grants MH 40899 and DA 10044 (P.G.), by a fellowship from the Swedish Society for Medical Research
(K.C.), by a travel fellowship from the Swedish Medical Research
Council (K.C.), and by a fellowship from Stiftelsen för
Internationalisering av högre utbilding och forskning (P.S.).
Correspondence should be addressed to Dr. Paolo Calabresi, Clinica
Neurologica, Dipartimento di Neuroscienze, Università di Roma
"Tor Vergata," Via di Tor Vergata 135, 00133 Rome, Italy. E-mail:
calabre{at}uniroma2.it.
 |
REFERENCES |
-
Altar CA,
Boyar WC,
Kim HS
(1990)
Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP.
Eur J Pharmacol
181:17-21[Medline].
-
Bibb JA,
Snyder GL,
Nishi A,
Yan Z,
Meijer L,
Fienberg AA,
Tsai LH,
Kwon YT,
Girault JA,
Czernik AJ,
Huganir RL,
Hemmings Jr HC,
Nairn AC,
Greengard P
(1999)
Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons.
Nature
402:669-671[Medline].
-
Calabresi P,
Mercuri NB,
Bernardi G
(1990)
Synaptic and intrinsic control of membrane excitability of neostriatal neurons. II. An in vitro analysis.
J Neurophysiol
63:663-675[Abstract/Free Full Text].
-
Calabresi P,
Maj R,
Pisani A,
Mercuri NB,
Bernardi G
(1992a)
Long-term synaptic depression in the striatum: physiological and pharmacological characterization.
J Neurosci
12:4224-4233[Abstract].
-
Calabresi P,
Pisani A,
Mercuri NB,
Bernardi G
(1992b)
Long-term potentiation in the striatum is unmasked by removing the voltage-dependent block of NMDA receptor channels.
Eur J Neurosci
4:929-935[Web of Science][Medline].
-
Calabresi P,
Pisani A,
Mercuri NB,
Bernardi G
(1996)
The corticostriatal projection: from synaptic plasticity to dysfunction of the basal ganglia.
Trends Neurosci
19:19-24[Web of Science][Medline].
-
Calabresi P,
De Murtas M,
Bernardi G
(1997a)
The neostriatum beyond the motor function: experimental and clinical evidence.
Neuroscience
78:39-60[Web of Science][Medline].
-
Calabresi P,
Saiardi A,
Pisani A,
Baik H-H,
Centonze D,
Mercuri NB,
Bernardi G,
Borrelli E
(1997b)
Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors.
J Neurosci
17:4536-4544[Abstract/Free Full Text].
-
Calabresi P,
Gubellini P,
Centonze D,
Sancesario G,
Morello M,
Giorgi M,
Pisani A,
Bernardi G
(1999a)
A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression.
J Neurosci
19:2489-2499[Abstract/Free Full Text].
-
Calabresi P,
Centonze D,
Gubellini P,
Bernardi G
(1999b)
Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP.
Neuropharmacology
38:323-326[Medline].
-
Calabresi P,
Centonze D,
Gubellini P,
Pisani A,
Bernardi G
(2000)
Acetylcholine-mediated modulation of striatal function.
Trends Neurosci
23:120-126[Web of Science][Medline].
-
Carvalho AL,
Kameyama K,
Huganir RL
(1999)
Characterization of phosphorylation sites on the glutamate receptor 4 subunit of the AMPA receptors.
J Neurosci
19:4748-4754[Abstract/Free Full Text].
-
Centonze D,
Gubellini P,
Picconi B,
Giacomini P,
Calabresi P,
Bernardi G
(1999)
Unilateral dopamine denervation blocks corticostriatal LTP.
J Neurophysiol
82:3575-3579[Abstract/Free Full Text].
-
Charpier S,
Deniau JM
(1997)
In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation.
Proc Natl Acad Sci USA
94:7036-7040[Abstract/Free Full Text].
-
Charpier S,
Mahon S,
Deniau JM
(1999)
In vivo induction of striatal long-term potentiation by low-frequency stimulation of the cerebral cortex.
Neuroscience
91:1209-1222[Web of Science][Medline].
-
Choi S,
Lovinger DM
(1997)
Decreased probability of neurotransmitter release underlies striatal long-term depression and postnatal development of corticostriatal synapses.
Proc Natl Acad Sci USA
94:2665-2670[Abstract/Free Full Text].
-
Dos Santos Villar F,
Walsh JP
(1999)
Modulation of long-term synaptic plasticity at excitatory striatal synapses.
Neuroscience
90:1031-1041[Web of Science][Medline].
-
Fienberg AA,
Hiroi N,
Mermelstein PG,
Song W-J,
Snyder GL,
Nishi A,
Cheramy A,
O'Callaghan JP,
Miller DB,
Cole DG,
Corbett R,
Haile CN,
Cooper DC,
Onn SP,
Grace AA,
Ouimet CC,
White FJ,
Hyman SE,
Surmeier DJ,
Girault J-A,
Nestler EJ,
Greengard P
(1998)
DARPP-32: regulator of the efficacy of dopaminergic neurotransmission.
Science
281:838-842[Abstract/Free Full Text].
-
Gerfen CR
(1992)
The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia.
Annu Rev Neurosci
15:285-320[Web of Science][Medline].
-
Gotz T,
Kraushaar U,
Geiger J,
Lubke J,
Berger T,
Jonas P
(1997)
Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons.
J Neurosci
17:204-215[Abstract/Free Full Text].
-
Greengard P,
Allen PB,
Nairn AC
(1999)
Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade.
Neuron
23:435-447[Web of Science][Medline].
-
Hemmings Jr HC,
Nairn AC,
Greengard P
(1984a)
DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor I.
J Biol Chem
259:14491-14497[Abstract/Free Full Text].
-
Hemmings Jr HC,
Greengard P,
Tung HYL,
Cohen P
(1984b)
DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.
Nature
310:503-505[Medline].
-
Jiang Z-C,
North RA
(1991)
Membrane properties and synaptic responses of rat striatal neurones in vitro.
J Physiol (Lond)
443:533-553[Abstract/Free Full Text].
-
Kawaguchi Y,
Wilson CJ,
Augood SJ,
Emson PC
(1995)
Striatal interneurones: chemical, physiological and morphological characterization.
Trends Neurosci
18:527-535[Web of Science][Medline].
-
Le Moine C,
Normand E,
Bloch B
(1991)
Phenotypical characterization of the rat striatal neurons expressing D1 dopamine receptor gene.
Proc Natl Acad Sci USA
88:4205-4209[Abstract/Free Full Text].
-
Morris BJ,
Simpson CS,
Mundell S,
Maceachern K,
Johnston HM,
Nolan AM
(1997)
Dynamic changes in NADPH-diaphorase staining reflect activity of nitric oxide synthase: evidence for a dopaminergic regulation of striatal nitric oxide release.
Neuropharmacology
36:1589-1599[Web of Science][Medline].
-
Pisani A,
Calabresi P,
Centonze D,
Bernardi G
(1997)
Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones.
Br J Pharmacol
120:1007-1014[Web of Science][Medline].
-
Roche KW,
O'Brien RJ,
Mammen AL,
Bernhardt J,
Huganir RL
(1996)
Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit.
Neuron
16:1179-1188[Web of Science][Medline].
-
Schiller J,
Schiller Y,
Clapham DE
(1998)
NMDA receptors amplify calcium into dendritic spines during associative pre- and post-synaptic activation.
Nat Neurosci
1:114-118[Web of Science][Medline].
-
Sibley DR,
Monsma Jr FJ
(1992)
Molecular biology of dopamine receptors.
Trends Pharmacol Sci
13:61-69[Medline].
-
Snyder GL,
Girault J-A,
Chen J,
Czernik AJ,
Kebabian JW,
Nathanson JA,
Greengard P
(1992)
Phosphorylation of DARPP-32 and inhibitor-1 in rat choroids plexus: regulation by factors other than dopamine.
J Neurosci
12:3071-3083[Abstract].
-
Snyder GL,
Fienberg AA,
Huganir RL,
Greengard P
(1998)
A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor.
J Neurosci
18:10297-10303[Abstract/Free Full Text].
-
Stern EA,
Jaeger D,
Wilson CJ
(1998)
Membrane potential synchrony of simultaneously recorded striatal spiny neurons in vivo.
Nature
394:475-478[Medline].
-
Surmeier DJ,
Bargas J,
Hemmings Jr HC,
Nairn AC,
Greengard P
(1995)
Modulation of calcium currents by D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons.
Neuron
14:385-397[Web of Science][Medline].
-
Surmeier DJ,
Song WJ,
Yan Z
(1996)
Coordinated expression of dopamine receptors in neostriatal medium spiny neurons.
J Neurosci
16:6579-6591[Abstract/Free Full Text].
-
Tingley WG,
Ehlers MD,
Kameyama K,
Doherty C,
Ptak JB,
Riley CT,
Huganir RL
(1997)
Characterization of the protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies.
J Biol Chem
272:5157-5166[Abstract/Free Full Text].
-
Towbin H,
Staehelin T,
Gordon J
(1979)
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc Natl Acad Sci USA
76:4350-4354[Abstract/Free Full Text].
-
Tsou K,
Snyder GL,
Greengard P
(1993)
Nitric oxide/cGMP pathway stimulates phosphorylation of DARPP-32, a dopamine- and cGMP-regulated phosphoprotein, in the substantia nigra.
Proc Natl Acad Sci USA
90:3462-3465[Abstract/Free Full Text].
-
Wickens JR,
Begg AJ,
Arbuthnott GW
(1996)
Dopamine reverses the depression of rat corticostriatal synapses which normally follows high-frequency stimulation of cortex in vitro.
Neuroscience
70:1-5[Web of Science][Medline].
-
Yan Z,
Hsieh-Wilson L,
Feng J,
Tomizawa K,
Allen PB,
Fienberg AA,
Nairn AC,
Greengard P
(1999)
Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin.
Nat Neurosci
2:13-17[Web of Science][Medline].
Copyright © 2000 Society for Neuroscience 0270-6474/00/20228443-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
M. A. Kheirbek, J. P. Britt, J. A. Beeler, Y. Ishikawa, D. S. McGehee, and X. Zhuang
Adenylyl Cyclase Type 5 Contributes to Corticostriatal Plasticity and Striatum-Dependent Learning
J. Neurosci.,
September 30, 2009;
29(39):
12115 - 12124.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Bonoiu, S. D. Mahajan, H. Ding, I. Roy, K.-T. Yong, R. Kumar, R. Hu, E. J. Bergey, S. A. Schwartz, and P. N. Prasad
Nanotechnology approach for drug addiction therapy: Gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons
PNAS,
April 7, 2009;
106(14):
5546 - 5550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Threlfell, S. Sammut, F. S. Menniti, C. J. Schmidt, and A. R. West
Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation
J. Pharmacol. Exp. Ther.,
March 1, 2009;
328(3):
785 - 795.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Meyer, E. Richer, S. A. Benkovic, K. Hayashi, J. W. Kansy, C. F. Hale, L. Y. Moy, Y. Kim, J. P. O'Callaghan, L.-H. Tsai, et al.
Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphology
PNAS,
November 25, 2008;
105(47):
18561 - 18566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Frank
Schizophrenia: A Computational Reinforcement Learning Perspective
Schizophr Bull,
November 1, 2008;
34(6):
1008 - 1011.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Tong and A. J. Gibb
Dopamine D1 receptor inhibition of NMDA receptor currents mediated by tyrosine kinase-dependent receptor trafficking in neonatal rat striatum
J. Physiol.,
October 1, 2008;
586(19):
4693 - 4707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Frank, A. A. Moustafa, H. M. Haughey, T. Curran, and K. E. Hutchison
Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning
PNAS,
October 9, 2007;
104(41):
16311 - 16316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Izhikevich
Solving the Distal Reward Problem through Linkage of STDP and Dopamine Signaling
Cereb Cortex,
October 1, 2007;
17(10):
2443 - 2452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Day and R. M. Carelli
The Nucleus Accumbens and Pavlovian Reward Learning
Neuroscientist,
April 1, 2007;
13(2):
148 - 159.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. Blythe, J. F. Atherton, and M. D. Bevan
Synaptic Activation of Dendritic AMPA and NMDA Receptors Generates Transient High-Frequency Firing in Substantia Nigra Dopamine Neurons In Vitro
J Neurophysiol,
April 1, 2007;
97(4):
2837 - 2850.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Cepeda and M. S. Levine
Where Do You Think You Are Going? The NMDA-D1 Receptor Trap
Sci. Signal.,
May 2, 2006;
2006(333):
pe20 - pe20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Nishi, Y. Watanabe, H. Higashi, M. Tanaka, A. C. Nairn, and P. Greengard
Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades
PNAS,
January 25, 2005;
102(4):
1199 - 1204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. D. Gould and H. K. Manji
DARPP-32: A molecular switch at the nexus of reward pathway plasticity
PNAS,
January 11, 2005;
102(2):
253 - 254.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Jouvert, M.-O. Revel, A. Lazaris, D. Aunis, K. Langley, and J. Zwiller
Activation of the cGMP Pathway in Dopaminergic Structures Reduces Cocaine-Induced EGR-1 Expression and Locomotor Activity
J. Neurosci.,
November 24, 2004;
24(47):
10716 - 10725.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. J. Reynolds, B. I. Hyland, and J. R. Wickens
Modulation of an Afterhyperpolarization by the Substantia Nigra Induces Pauses in the Tonic Firing of Striatal Cholinergic Interneurons
J. Neurosci.,
November 3, 2004;
24(44):
9870 - 9877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bracci, D. Centonze, G. Bernardi, and P. Calabresi
Engagement of Rat Striatal Neurons by Cortical Epileptiform Activity Investigated With Paired Recordings
J Neurophysiol,
November 1, 2004;
92(5):
2725 - 2737.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Centonze, A. Usiello, C. Costa, B. Picconi, E. Erbs, G. Bernardi, E. Borrelli, and P. Calabresi
Chronic Haloperidol Promotes Corticostriatal Long-Term Potentiation by Targeting Dopamine D2L Receptors
J. Neurosci.,
September 22, 2004;
24(38):
8214 - 8222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Picconi, F. Gardoni, D. Centonze, D. Mauceri, M. A. Cenci, G. Bernardi, P. Calabresi, and M. Di Luca
Abnormal Ca2+-Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism
J. Neurosci.,
June 9, 2004;
24(23):
5283 - 5291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Taverna, Y. C. van Dongen, H. J. Groenewegen, and C. M.A. Pennartz
Direct Physiological Evidence for Synaptic Connectivity Between Medium-Sized Spiny Neurons in Rat Nucleus Accumbens In Situ
J Neurophysiol,
March 1, 2004;
91(3):
1111 - 1121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. West and A. A. Grace
The Nitric Oxide-Guanylyl Cyclase Signaling Pathway Modulates Membrane Activity States and Electrophysiological Properties of Striatal Medium Spiny Neurons Recorded In Vivo
J. Neurosci.,
February 25, 2004;
24(8):
1924 - 1935.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ding and D. J. Perkel
Long-Term Potentiation in an Avian Basal Ganglia Nucleus Essential for Vocal Learning
J. Neurosci.,
January 14, 2004;
24(2):
488 - 494.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Dunah, A. C. Sirianni, A. A. Fienberg, E. Bastia, M. A. Schwarzschild, and David. G. Standaert
Dopamine D1-Dependent Trafficking of Striatal N-Methyl-D-aspartate Glutamate Receptors Requires Fyn Protein Tyrosine Kinase but Not DARPP-32
Mol. Pharmacol.,
January 1, 2004;
65(1):
121 - 129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Manji, I. I. Gottesman, and T. D. Gould
Signal Transduction and Genes-to-Behaviors Pathways in Psychiatric Diseases
Sci. Signal.,
November 4, 2003;
2003(207):
pe49 - pe49.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Centonze, C. Grande, E. Saulle, A. B. Martin, P. Gubellini, N. Pavon, A. Pisani, G. Bernardi, R. Moratalla, and P. Calabresi
Distinct Roles of D1 and D5 Dopamine Receptors in Motor Activity and Striatal Synaptic Plasticity
J. Neurosci.,
September 17, 2003;
23(24):
8506 - 8512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-P. Onn, A. A. Fienberg, and A. A. Grace
Dopamine Modulation of Membrane Excitability in Striatal Spiny Neurons is Altered in DARPP-32 Knockout Mice
J. Pharmacol. Exp. Ther.,
September 1, 2003;
306(3):
870 - 879.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Centonze, C. Grande, A. Usiello, P. Gubellini, E. Erbs, A. B. Martin, A. Pisani, N. Tognazzi, G. Bernardi, R. Moratalla, et al.
Receptor Subtypes Involved in the Presynaptic and Postsynaptic Actions of Dopamine on Striatal Interneurons
J. Neurosci.,
July 16, 2003;
23(15):
6245 - 6254.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Pessiglione, D. Guehl, Y. Agid, E. C. Hirsch, J. Feger, and L. Tremblay
Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease
Brain,
June 1, 2003;
126(6):
1392 - 1408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Fiorentini, F. Gardoni, P. Spano, M. Di Luca, and C. Missale
Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors
J. Biol. Chem.,
May 23, 2003;
278(22):
20196 - 20202.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bracci, D. Centonze, G. Bernardi, and P. Calabresi
Voltage-dependent membrane potential oscillations of rat striatal fast-spiking interneurons
J. Physiol.,
May 15, 2003;
549(1):
121 - 130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. S. Eyny and J. C. Horvitz
Opposing Roles of D1 and D2 Receptors in Appetitive Conditioning
J. Neurosci.,
March 1, 2003;
23(5):
1584 - 1587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gonzalez-Islas and J. J. Hablitz
Dopamine Enhances EPSCs in Layer II-III Pyramidal Neurons in Rat Prefrontal Cortex
J. Neurosci.,
February 1, 2003;
23(3):
867 - 875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Flores-Hernandez, C. Cepeda, E. Hernandez-Echeagaray, C. R. Calvert, E. S. Jokel, A. A. Fienberg, P. Greengard, and M. S. Levine
Dopamine Enhancement of NMDA Currents in Dissociated Medium-Sized Striatal Neurons: Role of D1 Receptors and DARPP-32
J Neurophysiol,
December 1, 2002;
88(6):
3010 - 3020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Saulle, D. Centonze, A. B. Martin, R. Moratalla, G. Bernardi, and P. Calabresi
Endogenous Dopamine Amplifies Ischemic Long-Term Potentiation via D1 Receptors
Stroke,
December 1, 2002;
33(12):
2978 - 2984.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-y. Kawaguchi and T. Hirano
Signaling Cascade Regulating Long-Term Potentiation of GABAA Receptor Responsiveness in Cerebellar Purkinje Neurons
J. Neurosci.,
May 15, 2002;
22(10):
3969 - 3976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bracci, D. Centonze, G. Bernardi, and P. Calabresi
Dopamine Excites Fast-Spiking Interneurons in the Striatum
J Neurophysiol,
April 1, 2002;
87(4):
2190 - 2194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Partridge, S. Apparsundaram, G. A. Gerhardt, J. Ronesi, and D. M. Lovinger
Nicotinic Acetylcholine Receptors Interact with Dopamine in Induction of Striatal Long-Term Depression
J. Neurosci.,
April 1, 2002;
22(7):
2541 - 2549.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Calabresi, E. Saulle, G. A. Marfia, D. Centonze, R. Mulloy, B. Picconi, R. A. Hipskind, F. Conquet, and G. Bernardi
Activation of Metabotropic Glutamate Receptor Subtype 1/Protein Kinase C/Mitogen-Activated Protein Kinase Pathway Is Required for Postischemic Long-Term Potentiation in the Striatum
Mol. Pharmacol.,
October 1, 2001;
60(4):
808 - 815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zhang, J. P. Steiner, G. S. Hamilton, T. P. Hicks, and M. O. Poulter
Regeneration of Dopaminergic Function in 6-Hydroxydopamine-Lesioned Rats by Neuroimmunophilin Ligand Treatment
J. Neurosci.,
August 1, 2001;
21(15):
RC156 - RC156.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|